VIBE PHARMACEUTICALS LLC

Biotech · Private

R Spondin protein therapeutic as an anabolic agent for osteoporosis and bone loss

ctt.upenn.edu →
Grants
$458K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of R-Spondin 1 as an Anabolic Agent for the Treatment of Estrogen Deficiency-induced Bone Loss$228,977
Federal grantDepartment of Health and Human Services · Phase I · Development of R-Spondin 1 as an Anabolic Agent for the Treatment of Estrogen Deficiency-induced Bone Loss$228,977
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3147Kinetiq——
3148ExQor Technologies Inc——
3149Lung Biotechnology——
3150VIBE PHARMACEUTICALS LLC——
3151SYNBAL INC——
3152ANANEO THERAPEUTICS INC——
3153BLOOD CELL TECHNOLOGIES LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.